作者
J-C Soria, Frances A Shepherd, J-Y Douillard, Jürgen Wolf, Giuseppe Giaccone, Lucio Crino, Federico Cappuzzo, Sunil Sharma, Stefan H Gross, Sasa Dimitrijevic, Lilla Di Scala, Humphrey Gardner, Lucia Nogova, Vassiliki Papadimitrakopoulou
发表日期
2009/10/1
期刊
Annals of oncology
卷号
20
期号
10
页码范围
1674-1681
出版商
Elsevier
简介
Background
Treatment options are scarce in pretreated advanced non-small-cell lung cancer (NSCLC) patients. RAD001, an oral inhibitor of the mammalian target of rapamycin (mTOR), has shown phase I efficacy in NSCLC.
Methods
Stage IIIb or IV NSCLC patients, with two or fewer prior chemotherapy regimens, one platinum based (stratum 1) or both chemotherapy and epidermal growth factor receptor tyrosine kinase inhibitors (stratum 2), received RAD001 10 mg/day until progression or unacceptable toxicity. Primary objective was overall response rate (ORR). Analyses of markers associated with the mTOR pathway were carried out on archival tumor from a subgroup using immunohistochemistry (IHC) and direct mutation sequencing.
Results
Eighty-five patients were enrolled, 42 in stratum 1 and 43 in stratum. ORR was 4.7% (7.1% stratum 1; 2.3% stratum 2). Overall disease control rate was 47.1%. Median …
引用总数
学术搜索中的文章
JC Soria, FA Shepherd, JY Douillard, J Wolf… - Annals of oncology, 2009